T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  • 0 views
  • 19 Sep, 2021
  • 3 locations
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side

peripheral t-cell lymphoma
angioimmunoblastic t-cell lymphoma
cyclophosphamide
adult t-cell leukemia/lymphoma
doxorubicin
  • 0 views
  • 15 Sep, 2021
  • 31 locations
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or S zary Syndrome (SS)

The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Szary Syndrome that have recently achieved disease control with previous systemic therapy.

systemic therapy
chemotherapy regimen
mycosis
sezary syndrome
maintenance treatment
  • 898 views
  • 17 Sep, 2021
  • 92 locations
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

lymphoma
progressive disease
solid tumor
prednisone
pd-l1
  • 2 views
  • 19 Sep, 2021
  • 14 locations
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

transplant may result in fewer problems and side effects. Eligibility Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to

lymphoma
blood transfusion
ejection fraction
estimated creatinine clearance
cell transplantation
  • 3 views
  • 19 Sep, 2021
  • 2 locations
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) . Both groups proceed to

extranodal nk/t-cell lymphoma
angioimmunoblastic t-cell lymphoma
adult t-cell leukemia
ejection fraction
large cell lymphoma
  • 3 views
  • 11 Sep, 2021
  • 2 locations
A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin

4 courses of D-GDP (Daratumumab in combination with Gemcitabine, Cisplatin, Dexamethasone) in terms of complete response in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS

  • 0 views
  • 08 Sep, 2021
  • 20 locations
Testing the Addition of an Anti-cancer Drug Hu5F9-G4 (Magrolimab) to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

fungoides or Sezary syndrome types of T-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Magrolimab and mogamulizumab are monoclonal antibodies that may interfere

lymphoma
serum pregnancy test
immunoglobulin
mycosis
monoclonal antibodies
  • 0 views
  • 19 Sep, 2021
  • 3 locations
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

peripheral t-cell lymphoma
brentuximab vedotin
hodgkin's disease
measurable disease
bendamustine
  • 0 views
  • 05 Sep, 2021
  • 1 location
Camrelizumab Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL

patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.

  • 0 views
  • 19 Sep, 2021
  • 3 locations